- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Janssen Research & Development Submits Complete Response to the U.S. FDA on XARELTO® (rivaroxaban) for the Reduction of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome
Supplemental New Drug Application for XARELTO® to reduce the risk of stent thrombosis in patients with acute coronary syndrome also resubmitted
Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
Compound in Development for Multiple Myeloma
FDA Approves NUCYNTA® ER (tapentadol) Extended-Release Oral Tablets for the Management of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
Clinical Trial Data Demonstrate Efficacy and Safety for First Opioid Indicated for Patients with Painful Diabetic Peripheral Neuropathy
Updated Coding and Payment on the Horizon for Circulating Tumor Cell Testing
CMS Action May Provide Increased Access for Patients
Janssen Healthcare Innovation Launches Care4Today™ Mobile Adherence Medication Reminder Platform
Free, secure mobile app and website designed to improve adherence to treatment regimens through self-directed reminders to take medications, refill prescriptions and visit healthcare providers